An archaeosome-adjuvanted vaccine and checkpoint inhibitor therapy combination significantly enhances protection from murine melanoma

From National Research Council Canada

Download
  1. (PDF, 970 KB)
DOIResolve DOI: https://doi.org/10.3390/vaccines5040038
AuthorSearch for: 1 ; Search for: 1 ; Search for: 1 ; Search for: 1 ; Search for: 1 ; Search for: 1 ; Search for: 1 
Name affiliation
  1. National Research Council Canada. Human Health Therapeutics
FormatText
TypeArticle
Journal titleVaccines
ISSN2076-393X
Volume5
Issue4
Pages# of pages: 16
Subjectcheckpoint inhibitor; PD-1; CTLA-4; tumor-infiltrating lymphocyte (TIL); cancer vaccine; CD8+ T cell response; archaeosome; prime-boost; B16; liposome; tumor vaccine; effector T cell (TE); effector memory T cell (TEM)
Abstract
Publication date
PublisherMDOI
Terms of use
LanguageEnglish
Peer reviewedYes
NPARC number23002442
Export citationExport as RIS
Report a correctionReport a correction
Record identifier1ff8f5a6-aba3-4909-bfa7-97e7093a9083
Record created2017-11-10
Record modified2019-03-11
Date modified: